Interleukin-6 (IL-6) plays a vital role in inducing cytokine storm in critical COVID-19 patients and a reduction in IL-6 levels by anti-inflammatory drugs is expected to ease CRS and reduce viral loads (Zhang C. et al., 2020). This evidence concerns the gene IL6 and congenital rubella syndrome.